Influence of various polymorphic variants of Cytochrome P450 Oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Chen, Xuan ^a   Pan, Li Qiang ^a   Naranmandura, Hua ^a   Zeng, Su ^a   Chen, Shu Qing ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; ISOENZYME; RECOMBINANT ENZYME; TESTOSTERONE;

ANIMAL CELL; ARTICLE; BIOCATALYSIS; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROLOGOUS EXPRESSION; HUMAN; IN VITRO STUDY; MISSENSE MUTATION; NONHUMAN; PHARMACOGENETICS; POR GENE; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CATALYSIS; CYTOCHROME P-450 CYP3A; DNA, COMPLEMENTARY; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SF9 CELLS; STEROID HYDROXYLASES;

EID: 84862162254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038495     Document Type: Article

References (48)

1. Guengerich FP, (2004) Cytochrome P450: what have we learned and what are the future issues? Drug metabolism reviews 36: 159-197.
2. Zhou SF, (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current drug metabolism 9: 310-322.
3. Özdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, et al. (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics and Genomics 10: 373.
4. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, et al. (2011) Polymorphic Variants of Cytochrome P450 2B6 (CYP2B6. 4-YP2B6. 9) Exhibit Altered Rates of Metabolism for Bupropion and Efavirenz: A Charge-Reversal Mutation in the K139E Variant (CYP2B6. 8) Impairs Formation of a Functional Cytochrome P450-Reductase Complex. Journal of Pharmacology and Experimental Therapeutics 338: 803-809.
5. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C, (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology & therapeutics 116: 496-526.
6. Zanger UM, Turpeinen M, Klein K, Schwab M, (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry 392: 1093-1108.
7. Hart SN, Zhong X, (2008) P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 4: 439-452.
8. Oneda B, Crettol S, Sirot EJ, Bochud M, Ansermot N, et al. (2009) The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenetics and Genomics 19: 877.
9. Zhang X, Li L, Ding X, Kaminsky LS, (2011) Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug metabolism and disposition 39: 1433-1439.
10. Miller WL, Agrawal V, Sandee D, Tee MK, Huang N, et al. (2011) Consequences of POR mutations and polymorphisms. Molecular and cellular endocrinology pp. 174-179.
11. Miller WL, Huang N, Agrawal V, Giacomini KM, (2009) Genetic variation in human P450 oxidoreductase. Molecular and cellular endocrinology 300: 180-184.
12. Kranendonk M, Marohnic CC, Panda SP, Duarte MP, Oliveira JS, et al. (2008) Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch Biochem Biophys 475: 93-99.
13. Schacter BA, Nelson EB, Marver HS, Masters BSS, (1972) Immunochemical evidence for an association of heme oxygenase with the microsomal electron transport system. Journal of Biological Chemistry 247: 3601.
14. Ilan Z, Ilan R, Cinti DL, (1981) Evidence for a new physiological role of hepatic NADPH: ferricytochrome (P-450) oxidoreductase. Direct electron input to the microsomal fatty acid chain elongation system. The Journal of biological chemistry 256: 10066.
15. Wang SL, Han JF, He XY, Wang XR, Hong JY, (2007) Genetic variation of human cytochrome P450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity. Drug metabolism and disposition 35: 176-179.
16. Pandey AV, Flück CE, Mullis PE, (2010) Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase. Biochemical and biophysical research communications 400: 374-378.
17. Shen AL, O'Leary KA, Kasper CB, (2002) Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. Journal of Biological Chemistry 277: 6536.
18. Otto DME, Henderson CJ, Carrie D, Davey M, Gundersen TE, et al. (2003) Identification of novel roles of the cytochrome P450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Molecular and cellular biology 23: 6103.
19. Gu J, Weng Y, Zhang QY, Cui H, Behr M, et al. (2003) Liver-specific deletion of the NADPH-cytochrome P450 reductase gene. Journal of Biological Chemistry 278: 25895.
20. Henderson CJ, Otto DME, Carrie D, Magnuson MA, McLaren AW, et al. (2003) Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. Journal of Biological Chemistry 278: 13480.
21. Huang N, Agrawal V, Giacomini KM, Miller WL, (2008) Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proceedings of the National Academy of Sciences 105: 1733-1738.
22. Sim SC, Miller WL, Zhong XB, Arlt W, Ogata T, et al. (2009) Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenet Genomics 19: 565-566.
23. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, et al. (2005) Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. The American Journal of Human Genetics 76: 729-749.
24. Flück CE, Nicolo C, Pandey AV, (2007) Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fundamental & clinical pharmacology 21: 399-410.
25. Marohnic CC, Panda SP, Martasek P, Masters BS, (2006) Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J Biol Chem 281: 35975-35982.
26. Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BS, et al. (2012) Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system. Drug Metab Dispos 40: 754-760.
27. Panda SP, Gao YT, Roman LJ, Martasek P, Salerno JC, et al. (2006) The role of a conserved serine residue within hydrogen bonding distance of FAD in redox properties and the modulation of catalysis by Ca2+/calmodulin of constitutive nitric-oxide synthases. J Biol Chem 281: 34246-34257.
28. Hart SN, Li Y, Nakamoto K, Wesselman C, Zhong X, (2007) Novel SNPs in cytochrome P450 oxidoreductase. Drug metabolism and pharmacokinetics 22: 322-326.
29. Agrawal V, Huang N, Miller WL, (2008) Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenetics and Genomics 18: 569-576.
30. Sandee D, Morrissey K, Agrawal V, Tam HK, Kramer MA, et al. (2010) Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenetics and Genomics 20: 677-686.
31. Agrawal V, Choi JH, Giacomini KM, Miller WL, (2010) Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase (POR). Pharmacogenetics and Genomics 20: 611-618.
32. Wang H, Yuan L, Zeng S, (2011) Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochemical Pharmacology 82: 1757-1763.
33. Lo HR, Chao YC, (2004) Rapid titer determination of baculovirus by quantitative real-time polymerase chain reaction. Biotechnology progress 20: 354-360.
34. Omura T, Sato R, (1964) The carbon monoxide-binding pigment of liver microsomes. Journal of Biological Chemistry 239: 2370-2378.
35. Han JF, Wang SL, He XY, Liu CY, Hong JY, (2006) Effect of genetic variation on human cytochrome p450 reductase-mediated paraquat cytotoxicity. Toxicological sciences 91: 42-48.
36. Wang RW, Newton DJ, Scheri TD, Lu AYH, (1997) Human Cytochrome P450 3A4-Catalyzed Testosterone 6β-Hydroxylation and Erythromycin N-Demethylation. Drug metabolism and disposition 25: 502-507.
37. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, et al. (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug metabolism and disposition 28: 1222-1230.
38. Eichelbaum M, Ingelman-Sundberg M, Evans WE, (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57: 119-137.
39. Meyer UA, (2004) Pharmacogenetics five decades of therapeutic lessons from genetic diversity. Nature Reviews Genetics 5: 669-676.
40. Flück CE, Mullis PE, Pandey AV, (2010) Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochemical and biophysical research communications 401: 149-153.
41. Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, et al. (2004) Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. The Lancet 363: 2128-2135.
42. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, et al. (2004) Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nature genetics 36: 228-230.
43. Black SD, Coon MJ, (1982) Structural features of liver microsomal NADPH-cytochrome P-450 reductase. Hydrophobic domain, hydrophilic domain, and connecting region. Journal of Biological Chemistry 257: 5929-5938.
44. Bonina TA, Gilep AA, Estabrook RW, Usanov SA, (2005) Engineering of proteolytically stable NADPH-cytochrome P450 reductase. Biochemistry (Moscow) 70: 357-365.
45. Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BSS, et al. (2012) Altered Human CYP3A4 Activity Caused by Antley-Bixler Syndrome-related Variants of NADPH-cytochrome P450 Oxidoreductase Measured in a Robust in vitro System. Drug metabolism and disposition: doi:10.1124/dmd.1111.042820.
46. Marohnic CC, Panda SP, McCammon K, Rueff J, Masters BSS, et al. (2010) Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Drug metabolism and disposition 38: 332-340.
47. Dhir V, Ivison HE, Krone N, Shackleton CHL, Doherty AJ, et al. (2007) Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Molecular Endocrinology 21: 1958-1968.
48. Pandey AV, Kempná P, Hofer G, Mullis PE, Flück CE, (2007) Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Molecular Endocrinology 21: 2579-2595.